HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keystone Labs Court-Ordered To Halt OTC Drug Manufacturing; Cosmetics Not Affected, It Says

This article was originally published in The Rose Sheet

Executive Summary

Keystone Labs agrees to cease manufacturing OTC drugs following a 2013 FDA warning letter and repeated GMP violations noted during inspections, including failure to investigate sources of contamination. Firm suggests it will continue making cosmetic hair- and skin-care formulas while outsourcing OTC product manufacturing.

You may also be interested in...



FDA Appears To Be Prepping For Cosmetics Regulatory Changes, Ingredient Review

Proposed regulatory reform legislation in the Senate would require FDA to review the safety of cosmetics ingredients, taking into account evaluations conducted by accredited third parties. In August, FDA requested quotes from the contractor community for developing a cosmetic hazard and risk assessment protocol and optional certification program “to show compliance with the protocol.”

FDA Consumer Health Product Recalls For May 4-25, 2016

Recalls reported by FDA for OTC drugs, nutritionals and personal care products.

ICCR Ushers Forth Updated Cosmetic GMP Guidelines From FDA

FDA’s draft revision of Cosmetic Good Manufacturing Practices takes into account international consensus formed through harmonization efforts under the International Cooperation on Cosmetics Regulations, says the agency. The recommendations update guidelines created in 1997 and revised in 2008.

Related Content

Topics

UsernamePublicRestriction

Register

RS122408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel